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ürich, Switzerland. Thehis study sought to evaluate long-term in vivo functionality, host cell repopulation, and remodeling of “off-the-shelf”
tissue engineered transcatheter homologous heart valves.Background Transcatheter valve implantation has emerged as a valid alternative to conventional surgery, in particular for elderly
high-risk patients. However, currently used bioprosthetic transcatheter valves are prone to progressive dysfunctional
degeneration, limiting their use in younger patients. To overcome these limitations, the concept of tissue engineered
heart valves with self-repair capacity has been introduced as next-generation technology.Methods In vivo functionality, host cell repopulation, and matrix remodeling of homologous transcatheter tissue-engineered
heart valves (TEHVs) was evaluated up to 24 weeks as pulmonary valve replacements (transapical access) in sheep
(n ¼ 12). As a control, tissue composition and structure were analyzed in identical not implanted TEHVs (n ¼ 5).Results Transcatheter implantation was successful in all animals. Valve functionality was excellent displaying sufﬁcient leaﬂet
motion and coaptation with only minor paravalvular leakage in some animals. Mild central regurgitation was detected
after 8 weeks, increasing to moderate after 24 weeks, correlating to a compromised leaﬂet coaptation. Mean and
peak transvalvular pressure gradients were 4.4  1.6 mm Hg and 9.7  3.0 mm Hg, respectively. Signiﬁcant matrix
remodeling was observed in the entire valve and corresponded with the rate of host cell repopulation.Conclusions For the ﬁrst time, the feasibility and long-term functionality of transcatheter-based homologous off-the-shelf tissue
engineered heart valves are demonstrated in a relevant pre-clinical model. Such engineered heart valves may
represent an interesting alternative to current prostheses because of their rapid cellular repopulation, tissue
remodeling, and therewith self-repair capacity. The concept of homologous off-the-shelf tissue engineered heart
valves may therefore substantially simplify previous tissue engineering concepts toward clinical translation.
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1321are inherently associated with progressive dysfunctional
degeneration, preventing their broader use in younger pati-
ent populations.
While preliminary attempts with decellularized xeno-
geneic and allogeneic heart valves have only shown limited
host cell repopulation in pre-clinical and clinical trials
(4–8), the concept of tissue engineered, living, and autolo-
gous heart valves with self-repair and remodeling capacity
has been proposed as a promising alternative to overcome
such limitations (9–15). In 2010, we reported successfully
merging transcatheter-based technologies with heart valve tis-
sue engineering (HVTE) on the basis of stem cell meth-
odology (12). However, this “classical” heart valve tissue
engineering concept comprising complex multistep procedures
such as cell harvest, cell expansion, seeding on scaffolds,
bioreactor in vitro culture, and time-critical implantation co-
ordination of the delicate, living engineered autologous heart
valves require high logistical andﬁnancial efforts. In this regard,
the concept of off-the-shelf (decellularized) homologous
tissue-engineered heart valves has recently been introduced as a
promising alternative to substantially simplify current HVTE
approaches toward routine clinical translation (16–18).
In this study and for the ﬁrst time, we investigate the long-
term in vivo functionality, host repopulation capacity, and
matrix remodeling of “off-the-shelf” homologous trans-
catheter tissue-engineered heart valves (TEHVs) as pulmo-
nary valve replacement in sheep.Methods
In vitro production of homologous cell-based trans-
catheter TEHV. Living stented TEHVs were engineered
as previously described (16,19) on the basis of rapid
degrading synthetic scaffolds and vascular-derived cells andFigure 1 Angiography of the Implantation Procedure
Function of the native valve was assessed prior to implantation (A,B). The inducing syst
Afterward, the position and functionality of the implanted valve was visualized (F). See adecellularized using a series of
enzymatic treatments (16). Please
see the expanded Methods sec-
tion in the Online Appendix for
further details. Sterilization was
obtained by immersion in 70%
EtOH and antibiotic treatment.
Decellularized TEHVs were
stored in fresh M-199 medium
at 4C.
Transapical implantation and in vivo performance of
TEHVs. To enable transapical delivery, the stented
TEHVs (length ¼ 27 mm, outer diameter ¼ 30 mm) were
crimped and loaded onto a custom-made inducing system
(outer diameter ¼ 12 mm). To evaluate in vivo functionality
and host repopulation capacity, TEHVs (n ¼ 12) were
transapically implanted as pulmonary valve replacement
in adult sheep (pulmonary annulus 24 to 26 mm, age
2.8  0.1 years, weight range 69  2 kg). The remaining
valves (n ¼ 5) served as reference (control) valves. All
animals received human care. The ethics committee (Veter-
inäramt, Gesundheitsdirektion, Kanton Zürich [197/2010],
Switzerland) approved the study in compliance with the
Guide for the Care and Use of Laboratory Animals, pub-
lished by the National Institutes of Health (NIH publication
No. 85-23) (20). Please see the expanded Methods section
in the Online Appendix for further details. The appropriate
position and functionality of the implanted valve was visu-
alized by angiography. In vivo functionality (heart rate,
mean and maximum transvalvular pressure gradient, and
grade of insufﬁciency) was monitored using transesophageal
echocardiography during the procedure, immediately
after implantation and after 1, 4, 8, 16, and 24 weeks
post-operatively. Insufﬁciency (central regurgitation) wasem was inserted (C) and the valve was delivered into the pulmonary artery (D,E).
ccompanying Online Video 1.
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1322graded as none to: 1) trivial; 2) mild; 3) moderate; and 4)
severe. Anticoagulation therapy was maintained for 7 days
after implantation. The TEHVs were explanted within 1 day
(n ¼ 2), and after 8 weeks (n ¼ 2), 16 weeks (n ¼ 4), and 24
weeks (n ¼ 4). Photographs were taken from all explanted
valves to macroscopically analyze tissue appearance.
Qualitative tissue analyses: (immuno-) histology and
scanning electron microscopy. Control (n ¼ 5) and
explanted TEHVs (n ¼ 12) were analyzed by (immuno-)
histology and scanning electron microscopy. Please see the
expanded Methods section in the Online Appendix for
further details.
Quantitative tissue analyses: tissue composition. The
total amount of DNA, sulfated glycosaminoglycans
(sGAGs), and collagen in the leaﬂets of control (n ¼ 5) and
explanted TEHVs after 8 (n ¼ 2), 16 (n ¼ 4), and 24 weeks
(n ¼ 4) as well as of native ovine valve leaﬂets (n ¼ 3) were
analyzed using biochemical assays. For each valve 2 samples
per leaﬂet were analyzed, resulting in 6 measurements per
valve. These measurements were averaged to represent an
average value for each valve. The values for DNA, sGAGs,
and collagen are expressed per milligram dry weight. PleaseFigure 2 Echocardiography of TEHV
Representative examples of valve behavior directly after implantation (A to C), after 4 (D t
with mobile and coapting leaﬂets at early follow-up time points (A,B,D,E). Mobility of the
to central regurgitation after 16 (L) and 24 weeks follow-up (O). TEHV ¼ tissue-engineersee the expanded Methods section in the Online Appendix
for further details on the assays.
Statistical analysis. Data are represented as mean SD. To
identify differences in tissue composition (DNA, sGAG, and
collagen) between the control valve leaﬂets and the explanted
leaﬂets at 16 and 24 weeks and that of native ovine valve
leaﬂets, a 1-way analysis of variance was performed with
Tukey’s post-hoc testing. The number of values for the
explanted valves after 8 weeks was too low (n¼ 2) to include in
the statistical analyses.Differenceswere considered signiﬁcant
when p < 0.05. Statistics were performed using GraphPad
Prism software (version 5.0d, San Diego, California).Results
Implantation and in vivo performance of TEHVs. The
transapical implantation procedures (n ¼ 12) were success-
ful. No perioperative morbidity or mortality occurred and all
valves could be deployed successfully at the target site (Fig. 1,
Online Video 1). In the early post-operative phase, 2 animals
presented with valve migration into the right ventricular
outﬂow tract and died within 24 h post-operatively. Theo F), 8 (G to I), 16 (J to L), and 24 weeks (M to O). Valve performance was excellent
leaﬂets was maintained, but coaptation decreased over time (G,H,J,K,M,N), leading
ed heart valve. See accompanying Online Videos 2, 3, and 4.
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1323remaining animals (n ¼ 10) made a swift recovery and
completed their respective follow-up without any compli-
cations. Serial echocardiography conﬁrmed sufﬁcient valve
function with mobile leaﬂets and excellent coaptation at the
early follow-up time points (Fig. 2, Online Videos 2 and 3).
No central regurgitation was observed at 4 weeks (n ¼ 10)
and mild central regurgitation at 8 weeks (n ¼ 10) (Table 1).
Only minor paravalvular leakage was initially observed in
some animals up to 1 week after implantation.
Long-term follow-up. While leaﬂet mobility was main-
tained on long-term follow-up, the coaptation slowly
decreased over time (Fig. 2, Online Video 4), which was
most likely due to merging of the leaﬂets with the valvular
wall at the level of the hinge area as well as the occurrence
of a single leaﬂet prolapse in some animals. Consequently,
mild to moderate central regurgitation could be observed at
16 weeks (n ¼ 8), that further increased to moderate central
regurgitation at 24 weeks (n ¼ 4), with 1 animal presenting
with severe insufﬁciency. Functional measurements
(Table 1) demonstrated stable mean and peak transvalvular
pressure gradients over time (4.4  1.6 mm Hg and 9.7
 3.0 mm Hg, respectively).
Macroscopic TEHV appearance. The implanted in vitro
grown homologous TEHV revealed thin and shiny tissue
formation in both valvular wall and leaﬂets (Figs. 3A to 3C).
All explanted TEHVs demonstrated shiny and pliable
leaﬂets and dense whitish valvular wall tissue, irrespective
of the implantation period (Figs. 3D to 3L). In all explants,
the valvular wall tissue was integrated into the surrounding
native valvular wall. Excellent coaptation of the explanted
valves was evident in the implant (Fig. 3A) and was main-
tained up to 8 weeks of implantation (Fig. 3D). Thereafter,
valve closure was incomplete in line with the observed
central regurgitation (Figs. 3G and 3J). Apparently, the lineTable 1
Echocardiographic Assessment of TEHV
at 1, 4, 8, 16, and 24 Weeks Follow-Up
Follow-Up
(Weeks) N
Heart Rate
(beats/min)
Mea
(mm
0 11 85  18 3.5
1 10 111  17 4.5
4 10 96  18 4.3
8 10 103  19 5.1
16 8 87  21 5.0
24 4 101  4 4.2
Overall mean d 97  20 4.4
Values are mean  SD unless otherwise indicated. Insufﬁciency (central regu
severe (4). The values in parentheses indicate the number of animals that re
animals. dP ¼ transvalvular pressure gradient; TEHV ¼ tissue-engineered heof attachment of the leaﬂets to the valvular wall shifted
upward in time, indicating tissue merging process at the level
of the hinge area (Figs. 3E, 3F, 3H, 3I, 3K, and 3L),
associated with a reduction in leaﬂet size with time.
TEHV repopulation and remodeling. Prior to implanta-
tion the TEHVs revealed no cellular remnants (Figs. 4A, 4F,
and 4K) and a well-developed extracellular matrix, mainly
consisting of collagen demonstrating an efﬁcient decellula-
rization procedure (Figs. 4P, 4U, and 4Z). After TEHV
deployment in the pulmonary position endogenous cellular
repopulation occurred rapidly with ﬁrst signs of cell inﬁl-
tration as early as 5 h after implantation (Figs. 4B, 4G, and
4L). Both leaﬂets and wall tissues were homogeneously
repopulated over time (Figs. 4C, 4D, 4H, 4I, 4M, and 4N),
with fastest repopulation at highest densities in the wall.
After 24 weeks, cell repopulation density in the leaﬂets
(Fig. 4E) and hinge area (Fig. 4J) approached that in the
valvular wall (Fig. 4O). Scaffold remnants remained longest
visible in the leaﬂets (Figs. 4B to 4E) with local increased
cell densities. Minimal depositions, most likely blood
platelets and ﬁbrin, were present at the surface of the whole
valve after 5 h (Figs. 4B, 4G, and 4L), but disappeared with
time. The valvular tissues demonstrated abundant amounts
of collagen that increased in density over time, in particular
in the hinge area (Figs. 4V, 4W to 4Y) and wall (Figs. 4AA
to 4DD), and to a lesser extent in the leaﬂets
(Figs. 4Q,R,S,T). Elastic matrix formation was evident in
the wall at 8 weeks and later time points (Figs. 4BB to
4DD). In the hinge area the formation of elastic ﬁbers was
visible after 16 weeks (Figs. 4X and 4Y) and in the leaﬂets at
24 weeks (Fig. 4T). Calciﬁcation was not detected in any of
the valves (data not shown).
TEHV cell phenotypes and distributions. Cells inﬁl-
trating the valve within 5 h after implantation were allDirectly After Implantation,
n dP
Hg)
Insufﬁciency
Grade
Insufﬁciency Grade
(per animal)
 0.7 1.2  0.4 1 (10/11)
2 (1/11)
 1.0 1.2  0.4 1 (8/10)
2 (2/10)
 1.1 1.1  0.3 1 (9/10)
2 (1/10)
 1.3 2.0  0.9 1 (3/10)
2 (5/10)
3 (1/10)
4 (1/10)
 2.8 2.6  0.9 1 (1/8)
2 (2/8)
3 (4/8)
4 (1/8)
 2.0 3.2  0.5 3 (3/4)
4 (1/4)
 1.6 d d
rgitation) was graded as none to trivial (1), mild (2), moderate (3), and
presented with the given insufﬁciency grade out of the total number of
art valve.
Figure 3 Macroscopic Appearance of Decellularized In-Vitro Grown TEHV
Macroscopic appearance of the implanted (A to C) and explanted (D to L) decellularized in vitro grown TEHV in closed conﬁguration (A,D,G,J), opened conﬁguration (B,E,H,K),
and as cross section (C,F,I,L). The implants and explants all revealed shiny and pliable leaﬂets. Complete closure was evident in the implant (A) and was maintained up to
8 weeks (D), while being incomplete thereafter (G,J). The line of attachment of leaﬂets to the wall moved upward in time (arrows), associated with a reduction in leaﬂet size
(E,F,H,I,K,L). TEHV ¼ tissue-engineered heart valve.
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1324vimentin positive (Figs. 5A, 5E, and 5I) and alpha-smooth
muscle actin (a-SMA)negative (Figs. 5M, 5Q, and5U).After
8 weeks, vimentin positive cells were identiﬁed mainly in
close vicinity of the polymeric scaffold remnants in the leaﬂet
(Fig. 5B) and hinge area (Fig. 5F), while more homoge-
nously distributed and in higher amounts in the valvular wall
(Fig. 5J). The cells in the leaﬂet and hinge area were all
a-SMA negative (Figs. 5N and 5R) and a-SMA positive in
the valvular wall (Fig. 5V). After 16 weeks, homogenously
distributed vimentin positive cells were observed in all
regions of the valve (Figs. 5C, 5G, and 5K). These cells were
a-SMA positive in the hinge area (Fig. 5S) and wall
(Fig. 5W) and sparsely a-SMA positive in the leaf-
let (Fig. 5Q). After 24 weeks, vimentin positive cells were
homogenously distributed over the valve (Figs. 5D, 5H, and
5L). The level of a-SMA seemed lower in the hinge area(Fig. 5T) and wall (Fig. 5X) as compared with the 16 weeks
explants. In the leaﬂets, more a-SMA positive cells were
identiﬁed (Fig. 5P) as compared with earlier time points.
After 8 weeks TEHV demonstrated partly conﬂuent
endothelial lining as observed by CD31 staining (Figs. 6A,
6D, and 6G). Similar features were observed at the surface of
the explants at 16 (Figs. 6B, 6E, and 6H) and 24 weeks
(Figs. 6C, 6F, and 6I). The cell lining showed the typical
cobblestone morphology at all time points, representative for
endothelial cells as visualized by scanning electron micro-
scopy (Figs. 6J to 6O). The degree of endothelialization
varied between locations and explants with decreasing
endothelialization at the hinge area with implantation time
(Figs. 6D to 6F) and increasing endothelialization of the
leaﬂet (Figs. 6A to 6C) and valvular wall surface with im-
plantation time (Figs. 6G to 6I).
Figure 4 Histology of the Implanted and Explanted TEHV
Hematoxylin and Eosin (H&E) (A to O) and Elastic von Gieson (EvG) (P to DD) staining of the implanted and explanted TEHV. The implants revealed no cellular remnants (A,F,K)
and a well-developed extracellular matrix (P,U,Z). The valvular tissues were homogeneously repopulated over time (B to E,G to J,L to O) with fastest repopulation at highest
densities in the wall. Scaffold remnants (closed arrows) remained longest visible in the leaﬂets (A to E). Minimal depositions (asterisks) were present at the surface after 5 h
(B,G,L), but disappeared with time. The valvular tissues demonstrated abundant amounts of collagen that increased in density over time (Q,R,S,T,V,W,X,Y,AA,BB,CC,DD),
mostly in the hinge area and wall. Elastic matrix formation (dashed arrows) was evident in all parts of the valve, appearing fastest in the wall (BB to DD), followed by the hinge
area (X,Y) and the leaﬂets (T). Scale bars represent 200 mm. TEHV ¼ tissue-engineered heart valve.
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1325Quantitative TEHV tissue analyses. DNA content
(Fig. 7A) of the leaﬂets increased with implantation time as
compared with the values before implantation (p < 0.01 at
16 weeks and p < 0.001 after 24 weeks). After 16 weeks,
DNA content was still lower than that in native leaﬂets
(p < 0.05), but after 24 weeks the DNA content in the
explanted TEHVs was similar to that in native ovine valve
leaﬂets. The amount of sGAGs (Fig. 7B) was lower in
TEHVs before implantation as compared with that in native
leaﬂets (p< 0.01) and was still lower in the 16-week explants
(p< 0.05). After 24 weeks sGAG content approached native
values. Collagen content (Fig. 7C) was higher after 16 and
24 weeks in vivo as compared with the values of theTEHVs before implantation (p < 0.05). Collagen content
was equal to that in native ovine leaﬂets at all time points.Discussion
Since the emergence of transcatheter heart valve implanta-
tions, which today are mostly used in elderly inoperable pa-
tients, an expansion to younger patient populations is
anticipated in the near future. A major limitation howeverd
as in classical surgical bioprosthesesdis the progressive
dysfunctional deterioration inherent to the nonliving animal-
derived tissue used in today’s bioprostheses. Furthermore,
accumulating clinical ﬁndings suggest that such degenerative
Figure 5 Cellular Phenotypes in Explanted TEHV
Vimentin (A to L) and alpha smooth muscle actin (a-SMA) (M to X) staining of TEHV. Vimentin positive cells were observed in all explants at all time points (A to L), with high cell
densities near the scaffold remnants. In the leaﬂets, no a-SMA expression was observed after 5 h (M) and 8 weeks (N). First signs of a-SMA positive cells appeared at 16 weeks
(O) and its level increased after 24 weeks (P). The hinge area demonstrated similar features (Q to T), though the level of expression seemed to decrease after 24 weeks (T) as
compared with 16 weeks (S). The cells in the valvular wall showed no a-SMA after 5 h (U), but abundant expression of a-SMA at 8 weeks (V) that seemed to decrease at 16
weeks (W) and further at 24 weeks (X). Scale bars represent 200 mm. TEHV ¼ tissue-engineered heart valve.
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1326processes may be even aggravated in transcatheter valves due
to the substantial mechanical stresses during the crimping and
deployment procedure. In the search for a next-generation
technology platform to overcome the limitations of today’s
bioprosthetic transcatheter heart valve prostheses, the con-
cept of HVTE using living autologous tissues with self-repair
capacity has created substantial hope for future heart valve
therapy concepts. In 2010, we have demonstrated the prin-
cipal feasibility to merge transcatheter-based technologies
and HVTE demonstrating transcatheter implantation of
stent-based TEHVs as pulmonary valve replacements in apre-clinical animal model (12). However, in this proof-of-
concept study, the generation of the used TEHV followed
the algorithm of the classical HVTE approach comprising
complex logistical and ﬁnancial efforts including cell and
expansion, scaffold seeding, bioreactor in vitro pre-condi-
tioning, and time-critical implantation coordination of the
delicate, living, autologous tissue-engineered heart valves.
In this study, we simpliﬁed the previously used HVTE
concept toward a substantially more translational and clini-
cally relevant methodology demonstrating long-term in vivo
functionality, host repopulation capacity, and matrix
Figure 6 Endothelialization of Explanted TEHV
CD31 staining (A to I) and scanning electron microscopy (SEM) (J to O) of explanted TEHV. Endothelialization was observed as a monolayer of CD31 positive cells lining the
valve explant and was conﬁrmed by its cobblestone morphology as observed by scanning electron microscopy (SEM). The degree of endothelialization varied between locations
and explants, but was observed at all time points. Scale bars represent 200 mm (A to I) and 50 mm (J to O). TEHV ¼ tissue-engineered heart valve.
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1327remodeling of off-the-shelf, tissue engineered decellularized
homologous transcatheter TEHVs in sheep. Conceptually,
off-the-shelf, homologous TEHVs carry signiﬁcant advan-
tages either when compared with decellularized xenogeneic/
allogeneic natural heart valves (16,18) or to the technolog-
ically and logistically demanding “classical” HVTE appro-
aches. By decellularization of homologous TEHV on the
basis of biodegradable PGA/P4HB scaffolds, we are able to
produce largely available off-the-shelf homologous starter
matrices at any clinically relevant size without the risk for
xenogeneic disease transmission (16). Importantly, this
off-the-shelf concept greatly simpliﬁes previous HVTE
concepts with regard to ﬁnancial and logistical efforts (16).
Last but not least, these decellularized matrices are designed
and adapted for transcatheter implantation, therewith further
enhancing their clinical relevance.
Overall, the TEHV function was sufﬁcient with mobile
leaﬂets and excellent coaptation at the early follow-up time
points. No central regurgitation was observed at 4 weeks and
mainly mild central regurgitation at 8 weeks. While leaﬂetmobility as well as a low transvalvular mean gradient was
maintained on all follow-up time points, valvular coaptation
slowly decreased over time, which was most likely due to a
principal design ﬂaw of these prototype TEHVs resulting in
merging of the leaﬂet base with the respective hinge areas.
This may be primarily related to the prototype stent and valve
design lacking important anatomical features such as sinuses
and thus leading to nonphysiological loading and insufﬁ-
cient washout in the hinge area, in particular during diastole.
To ensure viability, prevent deterioration, and allow for
growth and remodeling it is crucial that the host rapidly
repopulates these matrices after implantation. In our study,
the TEHVs demonstrated a remarkable repopulation and
remodeling capacity, pointing to the high potential of this
approach with regard to self-repair capacity.
Repopulation occurred rapidly already after a few hours. It
was fastest in the valvular wall, followed by the hinge area
and the leaﬂets, reaching similar DNA content to that of
native valves. In line with that, the collagen amount reached
native levels with increasing density over time and the
Figure 7
Composition of TEHV Leaﬂets Before Implantation
and After 8, 16, and 24 Weeks In Vivo
The amount of DNA (A), sGAGs (B), and hydroxyproline (C) as a measure for
collagen in TEHV leaﬂets before implantation (white bars), after 8 (light grey
bars), 16, and 24 weeks in vivo (medium grey bars), and of native ovine pulmo-
nary valve leaﬂets (dark grey bars). The data for the 8-week explants was not
taken into account in the statistical analyses, as the number of data points was
too low (n ¼ 2). DNA content increased in time, with values comparable to that in
native leaﬂets after 24 weeks. Sulfated glycosaminoglycan (sGAG) values are still
lower than that in native leaﬂets after 16 weeks, but approached native values
after 24 weeks. Collagen content was higher after 16 and 24 weeks as compared
with the values before implantation and was similar to those in native ovine
leaﬂets. HYP ¼ hydroxyproline; TEHV ¼ tissue-engineered heart valve.
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1328formation of elastic ﬁbers was visible. Remodeling of the
matrix occurred throughout the whole valve, but fastest in
the wall, followed by the hinge area and the leaﬂets, and as
such correlates with the observed rates of repopulation.
Furthermore, endothelialization of the surfaces occurred at
the valvular wall and the leaﬂets.
In comparison with native decellularized allogeneic or
xenogeneic valve prostheses that have been repeatedly re-
ported to show if at all only limited cell repopulation (4–8),
repopulation of our TEHVs appears to be substantially
more efﬁcient. Importantly, thus far, repopulation of valve
starter matrices was assumed to occur from the valve basis
upward associated with remodeling of the valve matrix.
This study suggests a potentially faster and more important
route of repopulation, which is by blood-borne cells. The
efﬁcacy of repopulation and subsequent production and
remodeling of extracellular matrix via this route may be
very potent and its mechanisms are subject to subsequent
studies.
Translation of this homologous off-the-shelf heart valve
tissue engineering from the low-pressure pulmonary circu-
lation to the systemic circulation appears feasible. Recent
pilot experiments by our group have demonstrated structural
integrity at systemic pressures of comparable valves (21–23).
As soon as the stent and valve delivery system have been
adapted to the aortic root, future studies will focus on long-
term systemic valve replacements.
Conclusions
We demonstrate for the ﬁrst time feasibility and long-term
functionality of transcatheter delivered homologous off-the-
shelf tissue-engineered heart valves with the potential for
self-repair. The concept of off-the-shelf TEHV may
represent a promising alternative to currently used valve
prostheses as of their rapid host cell repopulation and
remodeling capabilities toward native valve features within a
short time-span. Moreover, the off-the-shelf TEHV
concept may signiﬁcantly simplify previous, classical HVTE
concepts toward clinical translation.
Study limitations. Valvular coaptation decreased over time
by merging of the leaﬂet base with the respective hinge areas.
This shortcoming of the prototype TEHV requires stent
and scaffold design modiﬁcations and optimizations (i.e.,
the implementation of anatomical sinuses [24]) to ensure
and further improve long-term functionality of these next
generation valves.
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APPENDIX
For an expanded Methods section and supplemental videos, please see the
online version of this article.
